Literature DB >> 26093585

Cost of illness of medically treated benign prostatic hyperplasia in Hungary.

Fanni Rencz1, Ágnes Kovács, Valentin Brodszky, László Gulácsi, Zalán Németh, Gábor János Nagy, János Nagy, István Buzogány, Géza Böszörményi-Nagy, Attila Majoros, Péter Nyirády.   

Abstract

OBJECTIVE: To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary.
METHODS: A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective.
RESULTS: Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to <euro>876 (SD <euro>1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 %. High costs were related to informal care (<euro>243), medications (<euro>178) and private physician visits (<euro>132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p < 0.001). Mean costs of mild, moderate and severe patients were <euro>203, <euro>754 and <euro>2168, respectively.
CONCLUSIONS: To our knowledge, this is the first study in the literature that assessed indirect costs related to presenteeism in BPH. We found that costs of reduced productivity while working exceed costs of absence from work. As the retirement age is gradually increasing, the importance of presenteeism is getting more significant, especially in pursuit of sustainable employment.

Entities:  

Mesh:

Year:  2015        PMID: 26093585     DOI: 10.1007/s11255-015-1028-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

1.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

2.  Benign prostatic hyperplasia: counting the cost of its management.

Authors:  Roger S Kirby; Mike Kirby; John M Fitzpatrick
Journal:  BJU Int       Date:  2010-04       Impact factor: 5.588

3.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

Review 4.  Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.

Authors:  Mark Speakman; Roger Kirby; Scott Doyle; Chris Ioannou
Journal:  BJU Int       Date:  2014-10-16       Impact factor: 5.588

5.  Progression of lower urinary tract symptoms in older men: a community based study.

Authors:  J Kellogg Parsons; Timothy J Wilt; Patty Y Wang; Elizabeth Barrett-Connor; Douglas C Bauer; Lynn M Marshall
Journal:  J Urol       Date:  2010-03-29       Impact factor: 7.450

6.  Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study.

Authors:  N J A van Exel; M A Koopmanschap; J McDonnell; C R Chapple; R Berges; F F H Rutten
Journal:  Eur Urol       Date:  2005-11-02       Impact factor: 20.096

7.  [Disease burden of psoriasis associated with psoriatic arthritis in Hungary].

Authors:  Fanni Rencz; Valentin Brodszky; Márta Péntek; Orsolya Balogh; Eva Remenyik; Andrea Szegedi; Péter Holló; Sarolta Kárpáti; Hajnalka Jókai; Krisztina Herszényi; Emese Herédi; Sándor Szántó; László Gulácsi
Journal:  Orv Hetil       Date:  2014-11-30       Impact factor: 0.540

8.  Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA.

Authors:  Louise M A Braakman-Jansen; Erik Taal; Ina H Kuper; Mart A F J van de Laar
Journal:  Rheumatology (Oxford)       Date:  2011-12-16       Impact factor: 7.580

9.  [Health-related quality of life of the Hungarian population].

Authors:  Agota Szende; Renáta Németh
Journal:  Orv Hetil       Date:  2003-08-24       Impact factor: 0.540

10.  Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Richard-Olivier Fourcade; François Lacoin; Morgan Rouprêt; Alain Slama; Camille Le Fur; Emilie Michel; Axel Sitbon; François-Emery Cotté
Journal:  World J Urol       Date:  2011-09-03       Impact factor: 4.226

View more
  2 in total

Review 1.  EQ-5D in Central and Eastern Europe: 2000-2015.

Authors:  Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek
Journal:  Qual Life Res       Date:  2016-07-29       Impact factor: 4.147

2.  Long-term costs and survival of prostate cancer: a population-based study.

Authors:  Valentin Brodszky; Péter Varga; Judit Gimesi-Országh; Petra Fadgyas-Freyler; Imre Boncz; Péter Nyirády; Péter Riesz; Petra Baji; Márta Péntek; Fanni Rencz; László Gulácsi
Journal:  Int Urol Nephrol       Date:  2017-07-31       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.